An Outcome Analysis of Primary Membranous Nephropathy

Primary Membranous Nephropathy (PMN) is an autoimmune disease caused by the deposition of Immunoglobulin G and complement components on the subepithelial layer of the glomerular capillary wall. It affects 5-10 patients per million population and is the second cause of nephrotic syndrome in adults after diabetic kidney disease. For decades steroids and non-specific immunosuppressive medications have been advocated as a therapeutic option for patients with membranous nephropathy at increased risk of kidney failure because of persistent nephrotic syndrome. These medications, however, have major and potentially fatal adverse effects that offset their potential benefits and should be abandoned. Patients with PMN and non-nephrotic proteinuria (\<3.5 g per 24 h) have a good prognosis with a supportive therapy based on optimized inhibition of the Renin-Angiotensin-System with Angiotensin-Converting-Enzyme inhibitors (ACEi) and/or Angiotensin-Receptor-Blockers (ARBs). Without immunosuppression, however, approximately one-third of patients with PMN and nephrotic syndrome (NS) (proteinuria \>3.5 g per 24 h and/or hypoalbuminemia) progress to end stage kidney disease (ESKD). Steroids and non-specific immunosuppressive medications may achieve remission of the NS more effectively than placebo and supportive therapy but are associated with serious and potentially fatal complications that may offset the potential benefits of therapy. Thus, the 2012 Kidney Disease Improving Global Outcomes (KDIGO) guidelines recommended that the use of non- specific immunosuppressive therapy should be restricted to patients with persistent NS because, in this context, the reduced risk of ESKD could offset the risks of serious adverse events. The discovery of nephritogenic autoantibodies against podocyte M-type phospholipase A2 receptor (PLA2R) and thrombospondin type-1 domaincontaining protein 7A (THSD7A) antigens provided a clear pathophysiological rationale for interventions specifically targeting B cell lineages to prevent antibody production and subepithelial deposition. Anti-PLA2R antibody titer correlates with disease activity and patient outcome. Low autoantibody levels at diagnosis predict spontaneous remission, whereas high baseline anti-PLA2R antibody levels correlate with a reduced probability of spontaneous remission, are associated with progression to NS in patients with initial non-nephrotic proteinuria, and predict a high risk of relapse and progressive loss of kidney function. Moreover, decreasing anti-PLA2R antibody levels strongly predicts remission of proteinuria and response to various traditional and novel immunosuppressive treatments. Conceivably, in PLA2R-negative disease, PMN can be sustained by other nephritogenic autoantibodies such as anti-THSD7A antibodies that, similarly to anti-PLA2R antibodies, have been reported to predict disease activity and response to therapy.

Whether progression and response to treatment of patients with PMN can be affected not only by the overall titer of circulating anti-PLA2R autoantibodies, but also by their nature is matter of a lively debate. After almost 40 years of empirical treatment, the discovery of anti-PLA2R and anti-THSD7A autoantibodies provided the first clear pathophysiological rationale for interventions specifically aimed at preventing antibody production or their binding to specific antigens with subepithelial deposition of antibody-antigen immunocomplexes. The first-in-class anti-CD20 monoclonal antibody rituximab is safe and achieves remission in approximately two-thirds of patients with nephrotic membranous nephropathy. In PLA2R-related disease, remission is invariably preceded by depletion of anti PLA2R autoantibodies and relapse by their re-emergence into the circulation. Because of its superior risk/benefit profile as compared to non-specific immunosuppressive therapy, rituximab is now first-line therapy for patients with membranous nephropathy at risk of kidney failure. Novel monoclonal antibodies targeting CD20 cells (such as ofatumumab and obinutuzumab) and their differentiation (belimumab) or targeting long-living antibody producing CD38 memory cells (daratumumab, felzartamab) along with proteasome inhibitors such as bortezomib are being evaluated for the treatment of nephrotic patients with membranous nephropathy who are resistant or intolerant to rituximab. Complement inhibitor therapy might serve to stop the glomerular inflammatory process until the benefits of these medication become effective.

Researchers from the Department of Renal Medicine of Istituto di Ricerche Farmacologiche Mario Negri IRCCS, together with doctors from the Bergamo Hospital, were the first to document in 2002 that rituximab can recover totally or partially from the disease.

During the last twenty years, the Nephrology Unit of ASST-PG 23 (formerly, Ospedali Riuniti di Bergamo) become one of the most important disease specific Centers of excellence in the care of patients with PMN, more than 300 subjects were followed and treated with rituximab or other novel monoclonal antibodies in collaboration with "Centro di Ricerche Cliniche per le Malattie Rare Aldo e Cele Daccò", Ranica (BG) (Istituto Mario Negri IRCCS). The data collected at the routine visits of these patients represent an invaluable and unique source of information to describe the natural history of this rare disease and the evolution of the treatments. For this reason, we aim to create a data bank with the follow-up data of all the patients followed by the physicians of the Nephrology Unit in Bergamo and the Centro Daccò in Ranica who will agree to participate in the study and provide their consent to the use of their data for the research. Long-term data collection from a large patient sample may provide important insights regarding prognostic factors, characteristics of best responders to therapies, and estimation of the duration of unsuccessful treatment after which a patient can be considered a non-responder.

The variables evaluated in this study will complement and extend existing unknowledges on PMN, including provision of important information about the clinical course of the disease in patients receiving new treatments.

• Evaluation of disease progression [Time frame: Through study completion, an average of 6 months]
• Rate of GFR decline [Time frame: Through study completion, an average of 6 months]
• Blood parameter levels [Time frame: Through study completion, an average of 6 months]
• Incidence of adverse events [Time frame: Through study completion, an average of 6 months]
• Incidence of drug related adverse events [Time frame: Through study completion, an average of 6 months]